New research reveals that individuals who stop using new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who halt traditional diet and exercise regimens.
Published data in a major health publication points out that while obese individuals often shed a large proportion of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing these drugs must be cognizant of the risk of quick rebound weight gain when the treatment concludes," stated researcher Dr. Susan Jebb.
This pace of regain means a return to starting mass within about one and a half years.
Analyzing Approaches
The analysis, which looked at 37 of trials involving thousands of patients, contrasted the effects of the injectable medications with other pills.
The team emphasize that individuals who shed pounds through dieting generally see a slower creep back—perhaps 0.1 kg a month—post-intervention.
The Reason for the Fast Regain
Experts suggest the mechanism of the injections explains the accelerated rebound.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement means hunger is uncontrolled, making binge eating a significant risk."
A Lifelong Condition?
Health authorities suggest the injections for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians argue that, due to the significant potential of relapse, the treatment might need to be long-term.
This perspective is echoed by drug manufacturers, who state that the results "emphasize the long-term nature of excess weight," akin to managing diseases like diabetes.
Patient Testimonies
Individuals who have stopped the medication describe a powerful resurgence of cravings.
"I experienced something that goes on and you become extremely hungry," said a patient.
This difficulty is exacerbated if individuals have not developed lasting dietary or behavioural changes during treatment.
Widespread Use
Survey data indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is more common among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than public health services.
Ultimately, clinicians caution that while these medications are effective tools for shedding pounds, they are not a standalone cure and lasting health benefits relies on combined behavioural changes.
